Brenner B, Seligsohn U, Hochberg Z
Institute of Hematology, Rambam Medical Center, Haifa, Israel.
J Clin Endocrinol Metab. 1988 Jul;67(1):191-3. doi: 10.1210/jcem-67-1-191.
The effects of 1-deamino-8D-arginine vasopressin (DDAVP) on plasma factor VIII and von Willebrand factor (vWF) levels were studied in four patients with nephrogenic diabetes insipidus (NDI) from two unrelated families. While the urine osmolality remained low, the plasma levels of factor VIII and vWF rose 2- to 3-fold after infusion of 0.3 micrograms/kg DDAVP, compared to preinfusion levels. The degree of increase was similar in both NDI patients and normal subjects. We conclude that in NDI patients the end-organ resistance to DDAVP is confined to the kidneys and does not involve the sites from which factor VIII and vWF are released.
在来自两个无亲缘关系家族的4例肾性尿崩症(NDI)患者中,研究了1-去氨基-8-D-精氨酸加压素(DDAVP)对血浆凝血因子VIII和血管性血友病因子(vWF)水平的影响。尽管尿渗透压仍保持在低水平,但与输注前水平相比,在输注0.3微克/千克DDAVP后,凝血因子VIII和vWF的血浆水平升高了2至3倍。NDI患者和正常受试者的升高程度相似。我们得出结论,在NDI患者中,对DDAVP的终末器官抵抗仅限于肾脏,并不涉及凝血因子VIII和vWF的释放部位。